Overview

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Status:
Not yet recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.

Phase:

Phase 3

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Collaborator:

Teva Pharmaceuticals, Inc.

Treatments:

Trifarotene